Background/Aims: The bi-functional enzyme 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase-4 (PFKFB4) is highly expressed in many types of cancer and its requirement for tumor survival has been demonstrated in glioma, lung, and prostate cancers. However, whether PFKFB4 plays a role in the tumor metastasis remains uncertain. This study explores the role of PFKFB4 in tumor metastasis and its underlying mechanisms in breast cancer cells. Methods: The expression of PFKFB4 was first analyzed using the Cancer Genome Atlas (TCGA) dataset, and confirmed by immunohistochemical staining of tissue microarray and breast cancer tissues from patient samples. Gain-and loss-of-function approaches were used to investigate the effects of PFKFB4 on breast cancer cell migration in vitro. Orthotopic xenograft model and experimental metastasis model were used to assess the effects of PFKFB4 on breast cancer cell metastasis in vivo. ELISA and immunofluorescence staining were used to examine HA production. Quantitative RT-PCR and western blotting were used to explore the mRNA and protein levels of HAS2, respectively. Results: We found that PFKFB4 enhances the migration/invasiveness of breast cancer cells in vitro as well as in vivo. Notably, the effects of PFKFB4 on migration are mediated by induction of HAS2 expression and HA production. Moreover, PFKFB4-induced HAS2 up-regulation depends upon the activation of p38 signaling.
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner

Materials and Methods
Cell culture breast carcinoma cell lines MDA-MB-231 and T47D were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM, Biological Industries, Israel) containing 10% fetal bovine serum (Biological Industries, Israel) and 100U/ml penicillin/streptomycin (Hyclone, Logan, UT). Cells were maintained at 37°C in a humidified atmosphere with 5% CO 2 . If necessary, 10 μM of SB203580 (Cell Signaling Technology, Danvers, MA) or 10 μM of PD98059 (Sigma-Aldrich, St. Louis, MO) was added to the medium in order to inhibit p38 or ERK activities, respectively.
Tumor specimens and tissue microarray
Human breast cancer samples were obtained from the Chinese PLA General Hospital. All samples were invasive ductal carcinoma of the breast that were confirmed histologically. This study was approved by the institutional ethics committees of PLA General Hospital. Human breast cancer tissue array (BC081120c, Alenabio Company, Shanxi, China) includes 110 samples (100 human breast cancer samples and 10 normal samples).
Vector construction and establishment of stable cell lines
To construct the human PFKFB4 overexpression vector, DNA sequence encoding human PFKFB4 was PCR-amplified from human cDNA, using primers 5'-CGTCTAGAGCCA CCATGGCGTCCCCACGGGAATTG-3' and 5'-CGACGCGTTCACTGGTGAGCAGGCACCGTG-3' and cloned into the pLV-EF1α-MCS-IRES-Bsd plasmid (Biosettia, San Diego, CA). For gene silencing, shPFKFB4 DNA oligomers 5'-AAAAGCCCAACTCTC ATTGTCATGGTTGGATCCAACCATGACAATGAGAGTTGGGC-3' and 5'-AAAAGCTGGAGAGGCAAGAGAATGTTTGGATCCAAACATTCTCTTGCCTCTCCAGC -3'; shHAS2 DNA oligomers 5'-AAAAGCATTGTGAGAGGTTTCTATGTTGGATCCAACATAGAAACCTCTCACAC-3' were annealed and cloned into pLV-H1-EF1α-puro vector (Biosettia, San Diego, CA). The lentiviruses carrying the overexpression vectors, gene silencing vectors or empty vectors were produced according to manufacture's instruction. Lentivirus-containing medium was applied to cells in the presence of 8 μg/ml polybrene for 2 days, prior to selection with 10 μg/ml blasticidin (Bsd) or 1 μg/ml puromycin (Puro) for a week to establish stable cell lines.
Quantitative RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA), and reverse transcribed into cDNA using the TransScript First-Strand cDNA Synthesis SuperMix Kit (TransGen Biotech, Beijing, China) according to manufacturer's recommendations. qPCR was performed on a CFXTM Real-Time Thermal cycler (Bio-Rad, Hercules, CA) using a TransStart Top Green qPCR SupperMix kit (TransGen Biotech, Beijing, China). The primers used were as follows: HAS2, 5'-TGACAGGCATCTCACGAACC-3', and 5'-GGGTCTGCTGGTTTAGCCAT-3'; GAPDH, 5'-CTCTGATTTGGTCGTATTGGG-3', and 5'-TGGAAGATGGTGATGGGATT-3'.
Western blotting
Cells were washed in cold phosphate-buffered saline, collected and lysed in 1× RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1.0% NP-40, 0.5% Deoxycholic Acid, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 5 mM sodium pyrophosphate, 50 mM NaF, 10 mM b-glycerophosphate) with added phosphatase inhibitors (PhosSTOP, Roche Diagnostics, Vilvoorde, Belgium) and protease inhibitors (cOmplete, Roche Diagnostics, Vilvoorde, Belgium) for 30 min on ice. Lysates was centrifuged at 13, 000 rpm for 15 min at 4°C. Protein concentrations of the lysates were determined by BCA assay (Thermo Fisher Scientific, Waltham, MA). Samples were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked with 5% non-fat dry milk or 5% BSA in tris-buffered saline (TBS) with 0.1% Tween-20 for 1 h at room temperature and then incubated overnight at 4 °C with the appropriate antibody in blocking buffer as indicated. Following incubation with appropriate horseradish peroxidase-conjugated secondary antibodies, proteins were visualized using an enhanced chemiluminescence detection system (Thermo Fisher Scientific, Waltham, MA). This study was performed using the following antibodies: β-actin (sc-47778), STAT3 (sc-8019), p-STAT3 (sc-8001-R), p-ERK (sc-7976-R) and p-AKT (sc-135650), all of which were purchased from Santa Cruz Biotechnology. PFKFB4 (ab137785), HAS2 (ab199794), P38 (ab32142) and p-P38 (ab4822), all of which were purchased from Abcam. AKT (ZS-16190) and ERK (ZS-940), both of which were purchased from ZSGB-BIO. cells were seeded into the top transwell chamber (8μm pore size, 24 well plate) in 200 μl medium containing 1% FBS. The bottom chamber contained 500 μl medium containing 10% FBS. After 3 h (MDA-MB-231) or 48 h (T47D), the inserts were fixed with 4% paraformaldehyde and stained with crystal violet staining solution. Non-migrated cells were removed from top of the chamber with cotton swabs and bright-field photographs were taken using an OLYMPUS microscope (Olympus Co., Tokyo, Japan). Migrated cells of 5 random chosen areas were counted.
Wound healing ass
About 5×10 5 cells were seeded onto a 6-well plate in the presence of complete medium. Wound were generated by a conventional pipette tip when cells become confluent. The floating cells were aspirated and fresh media (1% FBS) was added to the cells. Images were taken immediately and at 24 h (MDA-MB-231) or 48 h (T47D) post-wound. Migration distance was determined using the Image J software as an average of closed area relative to the initial wound area.
Immunohistochemisty
Paraffin-embedded sections of human breast cancer tissues and tissue array were deparaffinized and antigen retrieval performed using citrate buffer (pH=6) or Tris EDTA buffer (pH=9), at a temperature of 97°C for 20 min. After exhaustion of endogenous peroxidase with methanol and hydrogen peroxide, slides were blocked with 0.3% BSA in 0.1 mol/L of tris-buffered saline for 30 min at room temperature, and incubated with primary antibody against PFKFB4 (Abcam, Cambridge, UK) overnight at 4°C. Antibody binding was detected using a peroxidase-conjugated secondary antibody at 37°C for 30 min. A DAB Substrate Kit was used to perform the chromogenic reaction. PFKFB4 expression levels in human breast tissues and tissue array were scored according to the extent of PFKFB4-positive cells and the staining intensity of each breast tissue sample. Specifically, 0-25%, 26-50%, 51-75%, and 76-100% were scored as 1, 2, 3 and 4, respectively. Tissues with brown, light brown, intermediate brown, and dark brown staining intensities were scored as 1, 2, 3, and 4, respectively. Five random fields (×20 magnification) were evaluated under a light microscope. The final scores were calculated by multiplying the scores of the intensity with those of the extent.
HA Assay
About 3×10 5 cells were seeded onto a 6-well plate in the presence of complete medium. After 48 h, the conditioned medium was collected for HA content quantification using the Hyaluronan DuoSet kit (R&D Systems, Abingdon, UK). HA concentration was calculated from a standard curve of the measured absorbance.
HABP Staining
Cells seeded on coverslips were washed once with PBS and fixed with 4% formaldehyde for 5 min. Cells were incubated with 2 μg/ml HA binding protein (HABP; Seikagaku, Japan) at room temperature for 1 h and incubated with 1 μg/ml FITC-conjugated streptavidin (Vector Laboratories, Burlingame, CA) for 30 min. Nuclei were counterstained with DAPI (Sigma-Aldrich, St. Louis, MO). Finally, sections were mounted with ProLongTM Gold antifade reagent (Thermo Fisher Scientific, Waltham, MA) and images were acquired by using a laser scanning confocal microscope (Leica, Wetzlar, Germany). The fluorescence intensity was quantified using ImageJ software.
In vivo evaluation of Lung Metastasis
To evaluate the lung metastasis, two types of mouse models were used. For the orthotopic model, PFKFB4-deficient or control MDA-MB-231 cells (1 × 10 6 in 100 μl basic DMEM) were injected into the second mammary fat pad of 8-week-old female NOD/ SCID mice (n=5 per group). Tumor volume was measured twice a week. The mice were sacrificed 2 months after injection. Tumor weight was measured, and the lung was embedded in paraffin and sliced for HE staining to examine metastasis. For the experimental metastasis model, PFKFB4-expressing or control T47D cells (2 × 10 6 in 100 μl basic DMEM) were injected into 8-weekold female NOD/SCID mice via the tail vein (n=5 per group). Mice were sacrificed 30 days after tail vein injection, and the lung were embedded in paraffin and sliced for HE staining to examine metastasis. Animal use complied with Nankai University Animal Welfare Guidelines.
TCGA data analysis
The data of 1098 patients with breast invasive carcinoma and 117 human normal tissues were downloaded from TCGA website (TCGA-BRCA). The normalized counts of the RNA expression of PFKFB4 were extracted and analysed. 
Statistical analysis
All data were analyzed using GraphPad Prism5 software (GraphPad Software, San Diego, CA). Results are presented as the mean ± SD with the exception of human samples and animal model data, which are presented as mean ± SEM. Statistical significance was determined by the Student's t-test or one-way ANOVA.
Results
PFKFB4 expression increases in breast cancer tissues
In order to determine PFKFB4 expression levels in breast cancer, we analyzed TCGA data of human breast cancer which included 1098 human breast cancer samples and 117 normal samples. This data analysis indicated that PFKFB4 expression increases in human breast cancer tissues versus normal breast tissues (Fig. 1a) . To confirm the above-mentioned data analysis, we immunocytochemically-stained a microarray containing 100 human breast cancer samples and 10 normal samples for PFKFB4 expression. The microarray results confirmed that PFKFB4 expression increases in human breast cancer tissues (even in early stages of the cancer) versus normal breast tissue (Fig. 1b, c) . In order to further validate Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry the above findings, we immunocytochemically-stained biopsies from breast cancer patients which included 32 breast cancer tissues and 21 peri-tumor tissues. The results again indicated that PFKFB4 expression increases in breast cancer tissues (Fig. 1d) .
PFKFB4 promotes the migration of breast cancer cells in vitro
In order to investigate the function of PFKFB4 on the migration of breast cancer cells, we stably knocked down PFKFB4 in MDA-MB-231 breast cancer cells and measured migration by the transwell assay and the razor-wound assay. The results showed that PFKFB4 knockdown significantly decreases the migration of MDA-MB-231 breast cancer cells in both assays (Fig. 2a-c) . Similar results were observed with the T47D breast cancer cells ( Fig. 2d-f ). To further confirm the role that PFKFB4 plays on the migration of breast cancer cells, we next ectopically expressed PFKFB4 in MDA-MB-231 breast cancer cells and measured migration by the transwell assay and the razor-wound assay. The results showed that PFKFB4 ectopic expression increases the migration of MDA-MB-231 breast cancer cells (Fig. 3a-c) . Similar results were observed with the T47D breast cancer cells (Fig. 3d-f ). Our findings collectively support the notion that PFKFB4 promotes the migration of breast cancer cells in vitro.
PFKFB4 promotes lung metastasis of breast cancer cells in vivo
In order to evaluate the impact of PFKFB4 on tumor dissemination in vivo, we employed two metastasis mouse models, namely the orthotopic xenograft mouse model and experimental metastasis mouse model. In the orthotopic xenograft mouse model, PFKFB4-deficient or control MDA-MB-231 breast cancer cells were injected into the second fat pad of immunodeficient NOD/SCID mice. We found that PFKFB4-deficient MDA-MB-231 breast cancer cells grow significantly smaller in terms of volume and weight versus control MDA-MB-231 breast cancer cells (Fig. 4a, b) . In addition, PFKFB4-deficient MDA-MB-231 breast cancer cells show a significantly decreased number of lung metastasis versus control MDA-MB-231 breast cancer cells (Fig. 4c, d ). In the experimental metastasis mouse model, PFKFB4-ectopically expressed or control T47D breast cancer cells were injected into immunodeficient NOD/SCID mice via the tail vein. We found that PFKFB4-ectopically expressed T47D breast cancer cells show a significantly increased number of lung metastasis versus control T47D breast cancer cells (Fig. 4e, f) . These observations collectively suggest that PFKFB4 plays a facilitative role in the metastasis of breast cancer cells in vivo. 
PFKFB4 increases HAS2 expression and HA production
Considering that PFKFB4 functions in glucose metabolism and cell migration and that HA functions in cell motility, we next tested whether PFKFB4 affects HA production in MDA-MB-231 and T47D breast cancer cells using the ELISA assay and immunofluorescence. Our results indicated that PFKFB4 ectopic expression in MDA-MB-231 and T47D breast cancer cells increases HA production versus controls (Fig. 5a-d) . Since HAS2 synthesizes HA, we tested whether PFKFB4 influences HAS2 expression in MDA-MB-231 and T47D breast cancer cells by measuring both HAS2 mRNA and protein levels. Our results showed a downregulation of HAS2 expression in PFKFB4-deficient MDA-MB-231 and T47D cells versus controls (Fig. 6a, b) . Conversely, our results showed an up-regulation of HAS2 expression in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells versus controls (Fig. 6c, d) . 
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PFKFB4-mediated migration requires HAS2 expression and HA accumulation in breast cancer cells
In order to determine whether PFKFB4-mediated migration requires HA, we administered hyaluronidase (HAase) to PFKFB4-ectopically expressed MDA-MB-231 and T47D cells and measured the number and distance of migrated cells. Our findings indicated that hyaluronidase administration eliminates the elevated migration capacity in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells versus controls (Fig. 7a-d) . In order to further confirm the above finding, we administered exogenous HA to PFKFB4-deficient MDA-MB-231 and T47D cells and measured the number and distance of migrated cells. Our findings indicated that exogenous HA administration rescues the depressed migration capacity in PFKFB4-deficient MDA-MB-231 and T47D cells versus controls (Fig. 7e-h) .
Finally, in order to determine whether PFKFB4-mediated migration requires HAS2, we silenced HAS2 expression in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells and measured the number and distance of migrated cells. Our findings showed that HAS2 silencing eliminates the elevated migration capacity in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells versus controls (Fig. 8a-d) . The above-mentioned findings collectively indicate that PFKFB4-mediated migration requires HAS2 and HA in breast cancer cells.
PFKFB4-induced HAS2 up-regulation and breast cancer cell migration depend on p38 phosphorylation
We next explored the underlying mechanism of HAS2 up-regulation induced by PFKFB4. Since ERK, p38, STAT3, and Akt signaling pathways regulate HAS2 expression, we therefore examined the effect of PFKFB4 ectopic expression on the phosphorylation of these signaling proteins in MDA-MB-231 and T47D breast cancer cells. We found that 
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Cellular Physiology and Biochemistry PFKFB4 ectopic expression enhances ERK phosphorylation and p38 phosphorylation, but does not affect STAT3 phosphorylation or Akt phosphorylation in MDA-MB-231 and T47D breast cancer cells versus control (Fig. 9a) . In order to examine whether the activated ERK and p38 signaling pathways are associated with the PFKFB4-induced up-regulation of HAS2, we treated PFKFB4-ectopically expressed MDA-MB-231 and T47D cells with either a pharmacological inhibitor of ERK (i.e., PD98059) or a pharmacological inhibitor of p38 (i.e., SB203580) and measured HAS2 expression. We found that SB203580-treatment (i.e., p38 inhibition) reduces HAS2 expression in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells versus untreated controls, but SB203580-treatment does not affect basal levels of HAS2 expression (Fig. 9b) . In contrast, we found that PD98059-treatment (i.e., ERK inhibition) does not affect HAS2 expression in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells versus untreated controls (Fig. 9c ). In addition, we observed that SB203580-treatment (i.e., p38 inhibition) eliminates the elevated migration capacity in PFKFB4-ectopically expressed MDA-MB-231 and T47D cells versus controls ( Fig. 10a-d) .
The above-mentioned results collectively suggest that the PFKFB4-induced up-regulation of HAS2 depends on the phosphorylation of p38.
Discussion
PFKFB4 is induced by hypoxia in multiple cancer cell lines and is also highly expressed in matched human lung, breast and colon tumor tissues versus normal tissues from the same patients both of which indicate a potential role in cancer initiation and/or progression [17] [18] [19] [20] . In this study, we found that PFKFB4 promotes breast cancer migration/invasion via a novel pathway i.e., PFKFB4/p38/HAS2 (HA). PFKFB4 overexpression phosphorylates p38 and activates unidentified downstream transcription factors that initiate HAS2 transcription and expression. This leads to HA accumulation in the tumor micro-environment and thereby creates a pro-metastatic micro-environment (Fig. 11) . PFKFB bi-functional enzymes are encoded by 4 genes (i.e., PFKFB1, PFKFB2, PFKFB3 and PFKFB4) of which PFKFB3 and PFKFB4 are particularly under extensive investigation. PFKFB3 and PFKFB4 expression increases in malignant tumors and plays a significant role in tumor cell proliferation and 
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Cellular Physiology and Biochemistry survival. In addition, PFKFB3 plays a role in tumor metastasis in head and neck squamous cell carcinoma and nasopharyngeal carcinoma [36, 37] . Previous reports indicate that HA accumulation occurs in numerous tumor types and thereby facilitates the progression and metastasis of carcinomas [38, 39] . In addition, HAS2 synthesizes HA (HMW-HA in particular) in a prolific fashion in tumors [27] . Consequently, therapeutic strategies that may either inhibit HAS2 expression or reduce HA accumulation in the tumor micro-environment in order to prevent tumor migration/invasion are of relevant interest. Several factors and signaling pathways play a role in HAS2 induction. In this regard, epidermal growth factor (EGF) increases HAS2 and HAS3 expression and thereby induces HA synthesis [40] . Platelet-derived growth factor (PDGF)-BB increases HAS2 expression through 
Cellular Physiology and Biochemistry the activation of phosphatidylinositol 3-kinase (PI3K) and mitogen-activated/extracellular signal-regulated kinase (MEK) [41] . UTP increases the phosphorylation of p38, ERK, and Ser-727 of STAT3 in human keratinocytes. p38, ERK, and STAT3 inhibitors partially block the activation of HAS2 expression which confirms the involvement of these pathways in the UTP-induced HAS2 response [42] . In this study, we found that PFKFB4 induces p38 and ERK phosphorylation, but not STAT3 or Akt phosphorylation. However, only PFKFB4-induced p38 phosphorylation (not ERK phosphorylation) elicits HAS2 expression and thereby contributes to tumor cell migration/invasion. p38 is activated by extracellular stress stimuli (e.g., UV light, heat, inflammatory cytokines, and growth factors). The p38 activation involves either a MAP kinase kinase (MAPKKs)-dependent mechanism or a MAPKK-independent mechanism [43] . We found that PFKFB4 overexpression increases glucose uptake and lactate secretion which facilitates glycolysis for glucose metabolism (unpublished data). The carbohydrate metabolism change in the microenvironment generates a stress stimulus to tumor cells that cause p38 activation. In addition, previous reports observed that TLR4-stimulated glycolysis involves a p38 MAPK-dependent HIF-1a accumulation in human monocyte-derived DCs [44] . However, p38 activation by glycolysis via a MAPKK-dependent or MAPKK-independent mechanism needs further investigation. The precursor substrates of HA include UDP-glucuronic acid and UDP-Nacetylglucosamine both of which use glucose as the original synthetic source [24] . Our previous studies showed that PFKFB4 overexpression not only increases glucose uptake and lactate secretion but also decreases ROS levels which suggests that PFKFB4 overexpression shifts glucose metabolism from oxidative phosphorylation to glycolysis (data not shown). However, the role of other glucose metabolic pathways (e.g., the hexosamine signaling pathway) which generate UDP-N-acetylglucosamine remain unexamined. This infers that PFKFB4 may also assist HA synthesis through other metabolic pathways which provides an area of future investigation.
Previous investigations have shown that both SB203580 (a p38 MAPK inhibitor) and 4-methylumbelliferone (4-MU; a HA inhibitor) suppress tumor cell migration/invasion in gastric, lung, breast, and pancreatic cancers [45] [46] [47] [48] [49] . However, due to the limited efficacy of these inhibitors clinical trials have not been initiated. In this regard, Jason et al., reported that 5-(n-(8-methoxy-4-quinolyl) amino) pentyl nitrate (5MPN; a newly designed selective PFKFB4 inhibitor) suppresses proliferation of multiple human tumor cell lines but not non-transformed epithelial cells in vitro [22] . However, the effect of 5MPN on tumor cell migration/invasion remains unexamined and provides a fertile area for future investigation. Furthermore, the effect of various combinations of the above-mentioned inhibitors on tumor cell migration/invasion based on the PFKFB4/p38/HAS2 (HA) pathway described in this study also provides a fertile area for future investigation.
Conclusion
In conclusion, our results demonstrate that PFKFB4 enhances the invasiveness of breast cancer cells in vitro and in vivo by inducing HA production. Moreover, PFKFB4-induced expression of HAS2 depends upon the activation of p38 signaling. This leads us to propose that PFKFB4, p38, and HAS2 may serve as therapeutic targets in the treatment of breast cancer.
